ZONTIVITY (vorapaxar), platelet aggregation inhibitor
CARDIOLOGY - New medicinal product
Opinions on drugs -
Posted on
Dec 10 2015
Reason for request
Inclusion
Insufficient actual benefit, in combination with acetylsalicylic acid and where appropriate with clopidogrel, in the reduction of atherothrombotic events in adult patients with a history of myocardial infarction
- ZONTIVITY has Marketing Authorisation, in combination with acetylsalicylic acid (ASA) and where appropriate with clopidogrel, in the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI).
- Its actual benefit is insufficient for reimbursement by National Health Insurance because of:
- a minor clinical added value in terms of morbidity and the lack of demonstrated efficacy in terms of mortality;
- and the greater occurrence of haemorrhagic events with the therapeutic strategy vorapaxar + ASA ± clopidogrel versus the strategy ASA ± clopidogrel.
Clinical Benefit
Insufficient |
- |
Therapeutic use
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments